Document is current
Any future updates will be listed below
-
Authors
Chowdhury, Saikat
Xiu, Joanne
Ribeiro, Jennifer R. http://orcid.org/0000-0002-1685-8568
Nicolaides, Theodore
Zhang, Jian
Korn, W. Michael
Poorman, Kelsey A.
Lenz, Heinz-Josef http://orcid.org/0000-0003-2178-9568
Marshall, John L.
Oberley, Matthew J.
Sledge, George W. Jr.
Spetzler, David
Kopetz, Scott http://orcid.org/0000-0001-9647-3416
Shen, John Paul http://orcid.org/0000-0003-4588-2775
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA234406, CA016672, CA016672, CA016672)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Cancer Prevention and Research Institute of Texas (RR180035)
Col. Daniel Connelly Memorial Fund
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 29 November 2023
Revised: 8 August 2024
Accepted: 12 August 2024
First Online: 4 September 2024
Competing interests
: HL: BMS, Merck, Bayer, Oncocyte, Fulgent, 3T Bioscience, Invitae, Abalos, AffiniT, Adagene, Replimune. JM: RESEARCH SUPPORT: 2cureX, OnDose, Arcus Biosciences; PAYMENT/HONORARIA: AstraZeneca, Merck, Bayer, Seagen, Pfizer, Takeda, Taiho Pharmaceutical; CONSULTING OR ADVISORY ROLE: Caris Life Sciences; OTHER: Indivumed (CMO). GWS: MEETING SUPPORT: Caris Life Sciences; STOCK/STOCK OPTIONS: Syndax, Caris Life Sciences, Tessa Pharm. SK: RESEARCH SUPPORT: Sanofi, Biocartis, Guardant Health, Array BioPharma, Genentech/Roche, EMD Serono, MedImmune, Novartis, Amgen, Lilly, Daiichi Sankyol CONSULTNG OR ADVISORY ROLE: Genentech, EMD Serono, Merck, Holy Stone Healthcare, Novartis, Lilly, Boehringer Ingelheim, AstraZeneca/MedImmune, Bayer Health, Redx Pharma, Ipsen, HalioDx, Lutris, Jacobio, Pfizer, Repare Therapeutics, Inivata, GlaxoSmithKline, Jazz Pharmaceuticals, Iylon, Xilis, Abbvie, Amal Therapeutics, Gilead Sciences, Mirati Therapeutics, Flame Biosciences, Servier, Carina Biotech, Bicara Therapeutics, Endeavor BioMedicines, Numab, Johnson & Johnson/Janssen, Genomic Health, Frontier Medicines, Replimune, Taiho Pharmaceutical, Cardiff Oncology, Ono Pharmaceutical, Bristol-Myers Squibb-Medarex, Amgen, Tempus, Foundation Medicine, Harbinger Oncology, Inc, Takeda, CureTeq, Zentalis, Black Stone Therapeutics, NeoGenomics Laboratories, Accademia Nazionale Di Medicina, Tachyon Therapeutics; STOCK/STOCK OPTIONS: Frontier Medicines; Iylon; Lutris; Navire; Xilis. JPS: RESEARCH SUPPORT: BostonGene, Celsius Therapeutics; CONSULTING OR ADVISORY ROLE: Engine Biosciences, NaDeNo Nanoscience. JX, JRR, TN, JZ, KAP, MJO, GWS, and DS: employees of Caris Life Sciences.
: This study was conducted in accordance with guidelines of the Declaration of Helsinki, Belmont report, and U.S. Common rule. In keeping with 45 CFR 46.101(b) (4), this study was performed utilizing retrospective, deidentified clinical data. As such, it is considered Institutional Review Board (IRB) exempt and no patient consent was required. Exempt status was determined by Western IRB.
